The entire stake was acquired by Kotak Mahindra Mutual Fund at par. The deal comes less than two years after Emcure Pharmaceuticals’ public listing and is one of the biggest block transactions in the pharmaceutical sector this year.
Shares rose to Rs. 1,700 changed hands, a discount to the prevailing market price, a common feature in large institutional transactions aimed at facilitating bulk share sales.
Emcure is in focus among analysts due to its strong position in chronic therapies and improving export prospects.
According to a recent note by YES Securities, the company is expected to benefit from multiple growth drivers over the next few years. Its core gynecology franchise, one of the strongest in the domestic pharmaceutical market, is projected to deliver double-digit growth, aided by moderation in the traction of its iron deficiency portfolio and ferric carboxymaltose products in the hospital business.
The brokerage also highlights new product launch opportunities in emerging categories in women’s healthcare and the company’s distribution system for legacy cardiac and diabetes brands acquired from Sanofi. Analysts believe the partnership could help Emcure strengthen specialist doctor engagement and support growth in its own cardiology portfolio.
On the international front, Emcure is expected to benefit from scale-up of Amphotericin B production with dedicated manufacturing facilities supporting growth in export revenue.
YES Securities estimates that Emcure can grow revenue by 12-13% annually over the next three years, with operating margins gradually improving.
The company has built a diversified pharmaceutical business spanning women’s health, cardiology, blood-related therapies, oncology and international formulations. It also maintains a growing presence in regulated and emerging export markets.
As a trusted and reliable news source
Add now!
(You can now subscribe to our ETMarkets WhatsApp channel)